Zentalis Pharmaceuticals faces a precarious outlook characterized by a lack of recurring revenue and a rapid depletion of capital reserves to fund its high-intensity R&D pipeline. The company's reliance on non-recurring milestone payments has resulted in extre...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.59-20.4% vs -$0.49 | — vs — |
Q2 2026 May 12, 2026 | -$0.50-2.0% vs -$0.49 | — vs — |
Q2 2026 Mar 26, 2026 | -$0.49-19.5% vs -$0.41 | — vs — |
Q4 2025 Nov 10, 2025 | -$0.37+24.5% vs -$0.49 | — vs — |
Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) received a bullish initiation from William Blair on Tuesday, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib.
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 3,753,525 shares of the company's stock, valued at approximately $18,205,000. BlackRock Inc. owned approximately 5.27% of Zentalis Pharmaceuticals as
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:
Benchmark ZNTL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zentalis Pharmaceuticals, Inc. (ZNTL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.52 | $179.39M | -1.32 | -100% | — | -49.53% | — | |
| $206.64 | $43.93B | -34.73 | — | — | -96.44% | — | |
| $107.39 | $8.83B | -29.10 | -16.72% | -285.41% | -21.5% | — | |
| $15.83 | $2.04B | 7.65 | 20.38% | 100.84% | 59% | — | |
| $295.51 | $8.24B | -21.92 | -100% | — | -34.15% | — | |
| $54.29 | $8.31B | 19.60 | 87.32% | 55.22% | 72.3% | — |
Zentalis Pharmaceuticals, Inc. (ZNTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Zentalis Pharmaceuticals, Inc. (ZNTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 18, 2026·SEC
May 27, 2026·SEC
Get notified when ZNTL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zentalis Pharmaceuticals, Inc. (ZNTL) stock FAQ — growth, dividends, profitability & financials explained
Zentalis Pharmaceuticals, Inc. (ZNTL) saw revenue decline by 100.0% over the past year.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $174.9M for fiscal year 2025.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a return on equity (ROE) of -49.5%. Negative ROE indicates the company is unprofitable.
Zentalis Pharmaceuticals, Inc. (ZNTL) had negative free cash flow of $161.1M in fiscal year 2025, likely due to heavy capital investments.
